Dr. Mitchell Croatt (Chemistry & Biochemistry) received new funding from the National Institutes of Health National Cancer Institute for the project “TAK1 Inhibition by (5Z)-7-Oxozeaenol Analogues for Anticancer Leads.”
This project will develop new anticancer drug leads based on the natural product pharmacophore.
